Shilpa Medicare Ltd

Small Cap

Healthcare Sector

reflects a positive outlook for the share price

reflects a neutral outlook for the share price

reflects a negative outlook for the share price

The analysts information is for reference only and does not\n  represents an investment recommendation.

Analyst recommendation reflect the views of analysts who follow and write research reports.

Company Information is an introduction to the company’s business that details what it sell, how it was founded, what their mission is, how they manufacture or source their products, and why they serve customers.

Antique Broking maintains a 'Buy' rating on Shilpa Medicare but lowers the target price to ₹1,090 due to regulatory delays and cost pressures. Despite a strong Q4FY25 revenue growth of 13%, the firm has cut revenue estimates for FY26/27 and adjusted EBITDA margin assumptions. However, it remains optimistic about the long-term monetization potential of Shilpa's product pipeline.

Antique Cuts Target Price for Shilpa Medicare - 28 May, 2025

Shilpa Medicare reported a 41% decline in net profit for Q4 FY25, despite a revenue increase. Analysts see potential in upcoming product launches. The company declared a Rs 1 dividend per share for FY 2024-2025.

Shilpa Medicare Reports Q4 Losses and Future Prospects - 27 May, 2025

Shilpa Medicare's subsidiary, Shilpa Biocare, has entered a strategic partnership with Orion Corporation to distribute Recombinant Human Albumin in Europe, enhancing market access and safety.

Shilpa Medicare Partners with Orion for Albumin Distribution - 23 May, 2025

Shilpa Medicare's shares increased by nearly 5% following the receipt of an Establishment Inspection Report (EIR) from the USFDA for its Unit-1 facility, classified as Voluntary Action Indicated (VAI). The company also secured European GMP accreditation for its biologics unit, enhancing its regulatory standing.

Shilpa Medicare Shares Surge on USFDA Approval - 15 May, 2025

Shilpa Medicare's Unit VI in Bengaluru has received Good Manufacturing Practice (GMP) approval from the European Medicines Agency, enhancing its ability to market innovative drug delivery systems in the EU.

Shilpa Medicare Secures EMA GMP Certification - 06 May, 2025

Shilpa Medicare's subsidiary, Shilpa Biologics, has obtained European GMP certification for its Dharwad plant, allowing the production of test batches following a successful inspection by Austrian authorities.

Shilpa Medicare Secures EU GMP Certification - 05 May, 2025

Price to Earnings Ratio or Price to Earnings Multiple is the ratio of the share price of a stock to its earnings per share (EPS). It provides an indication of whether a stock at its current market price is expensive or cheap.

The price/earnings-to-growth ratio, or the PEG ratio, is a metric that helps investors value a stock by taking into account a company's market price, its earnings, and its future growth prospects.

Enterprise value (EV) is the total value of a company, defined in terms of its financing. It includes both the current share price (market capitalization) and the cost to pay off debt (net debt, or debt minus cash).

Alpha measures the amount that the investment has returned in comparison to the market index or other broad benchmark that it is compared against.

Beta measures a stock's volatility, the degree to which its price fluctuates in relation to the overall stock market. In other words, it gives a sense of the stock's risk compared to that of the greater market.

Dividend yield measures the quantum of earnings by way of total dividends that investors make by investing in that company.

The debt-to-total-assets ratio shows how much of a business is owned by creditors (people it has borrowed money from) compared with how much of the company's assets are owned by shareholders.

Operating cash flow (OCF) is a measure of the amount of cash generated by a company's normal business operations. Operating cash flow indicates whether a company can generate sufficient positive cash flow to maintain and grow its operations.

This widget shows the information about the stock's peers in consideration along with the different data for those peers so that the user can compare the stock with the other similar stock and invest accordingly.

Promoter holding is the amount of share of the company that is owned by the promoters. The promoters are the company's founders, who hold a majority stake in the company's capital.

A foreign institutional investor (FII) is an investor or investment fund investing in a country outside of the one in which it is registered or headquartered.

A mutual fund is a pool of money managed by a professional Fund Manager. It is a trust that collects money from a number of investors who share a common investment objective and invests the same in equities, bonds, money market instruments, and other securities.

Retail investors execute their trades through traditional or online brokerage firms or other types of investment accounts. Retail investors purchase securities for their own personal accounts and often trade in dramatically smaller amounts as compared to institutional investors.

This widget shows the bifurcation of stocks based on the percentage of stake with the different types of shareholders.

This widget will help value the stock based on the Price to Earning ratio of the stock and compare the valuation with the industry value and other similar stocks. It even shows the timeline of the valuation of the stock and its highest and lowest valuation over time.
A Time Series data is provided which compares the historical stock PE with Industry PE over the period of 5 years.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

Foreign Institutions have increased holdings from 9.90% to 10.97% in Mar 2025 quarter

This section gives you an insight into how the FII Holding has changed for the stock over last few quarters.

FII Holding Up

In the last 1 month, SHILPAMED stock has moved up by 43.0%

This section gives you an insight into the price movement of the stock for the last few quarters.

Price Rise

Revenue is up for the last 2 quarters, 320.79 Cr → 340.68 Cr (in ₹), with an average increase of 5.8% per quarter

This section gives you an insight into how the revenue of the company has moved for the last few quarters.

Revenue Rich

In the last 1 year, SHILPAMED has outperformed top 5 stocks with highest market-cap in Pharmaceuticals

This section gives you an insight into why this company has been the best in its industry for the last 1 year.

Best in 1 Year

In the last 3 years, Torrent Pharmaceuticals Ltd has given 124.2% return, outperforming this stock by 16.7%

This section gives you an insight into how the peers have performed as compared to this company in the last 3 years.

Against Peers

Promoters holdings remained unchanged at 44.23% of holdings in Mar 2025 quarter

This section gives you an insight into how the Promoter Holding has changed for the stock over the last few quarters.

Promoter Holding Unchanged

Netprofit is down for the last 2 quarters, 31.78 Cr → 14.51 Cr (in ₹), with an average decrease of 54.3% per quarter

This section gives you an insight into how the profit for the company has been for the last few quarters.

Profit Down

Mutual Funds have decreased holdings from 4.89% to 4.05% in Mar 2025 quarter

This section gives you an insight into how the Mutual Funds Holding has changed for the stock over last few quarters.

MF Holding Down

Retail Investor have decreased holdings from 37.60% to 37.25% in Mar 2025 quarter

This section gives you an insight into how the Retail Investors Holding has changed for the stock over last few quarters.

Retail Holding Down

BSE Healthcare

BSE Small-Cap

Bandhan Small Cap Fund Direct Growth

ICICI Prudential ELSS Tax Saver Fund Direct Plan Growth

ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth

Bandhan Innovation Fund Direct Growth

Motilal Oswal Nifty Microcap 250 Index Fund Direct Growth

Shilpa Medicare Ltd’s net profit fell -40.78% since last year same period to ₹14.51Cr in the Q4 2024-2025. On a quarterly growth basis, Shilpa Medicare Ltd has generated -54.34% fall in its net profits since last 3-months.

Name	Value	Action
MACD level (12,26)	-1.45	Bearish
CCI (20)	116.58	Bearish
RSI (14)	32.8	Neutral
Momentum (10)	-1.6	Bullish
ADI (14)	32.29	Bearish
Ultimate Oscillator (7,14,28)	29.4	Bearish

Name	Value	Action
SMA (20)	900.69	Bearish
EMA (20)	900.44	Bearish
VWMA (20)	899.72	Bearish
SMA (50)	903.07	Bearish
EMA (50)	902.08	Bearish
SMA (200)	907.37	Bearish
EMA (200)	904.01	Bearish
KAMA (200)	901.87	Bearish
DEMA (200)	904.38	Bearish

Shilpa Medicare Ltd (SHILPAMED)

Summary

Overall

Oscillators

Moving Averages